Higher sales on stronger financial footing, page-2

Hi Trae

The key takaway that some in the  market may take some notice of in coming days (and weeks) is along the lines that a bird in the hand is worth more than 2 in the bush.

I would of course like to have seen sales at double their present level and there has been delay in getting to where we are.  But where we are is on top of a profitable business model ...... notwithstanding the additional expense of more staff and a flashy advertising campaign.

Not many small biotechs have profitable pipelines.  Cellmid is one of them.

cheers